| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | 
|---|---|---|---|---|
| Gross Sales | 377.98 | 214.52 | 35.34 | 14.17 | 
| Excise Duty | 0 | 0 | 0 | 0 | 
| Net Sales | 377.98 | 214.52 | 35.34 | 14.17 | 
| Other Operating Income | 20.27 | 0 | 0 | 0 | 
| Other Income | 19.26 | 2.82 | 3.68 | 0.46 | 
| Total Income | 417.51 | 217.34 | 39.02 | 14.63 | 
| Total Expenditure | 308.55 | 172.92 | 22.67 | 12.22 | 
| PBIDT | 108.96 | 44.42 | 16.35 | 2.41 | 
| Interest | 21.55 | 9.45 | 2.14 | 0.57 | 
| PBDT | 87.41 | 34.97 | 14.22 | 1.85 | 
| Depreciation | 16.84 | 10.02 | 1.78 | 0.71 | 
| Minority Interest Before NP | 0 | 0 | 0 | 0 | 
| Tax | 15.56 | 8 | 1.43 | 0.17 | 
| Deferred Tax | -3.33 | -15.76 | 2.58 | -0.02 | 
| Reported Profit After Tax | 58.34 | 32.71 | 8.43 | 0.99 | 
| Minority Interest After NP | -0.22 | 1.26 | 0 | 0 | 
| Net Profit after Minority Interest | 58.56 | 31.45 | 8.43 | 0.99 | 
| Extra-ordinary Items | 0 | 0 | 0 | 0 | 
| Adjusted Profit After Extra-ordinary item | 58.56 | 31.45 | 8.43 | 0.99 | 
| EPS (Unit Curr.) | 16.12 | 13.67 | 8.87 | 1.2 | 
| Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 
| Dividend (%) | 0 | 0 | 0 | 0 | 
| Equity | 46.05 | 30.51 | 9.82 | 8.74 | 
| Public Shareholding (Number) | 0 | 0 | 0 | 0 | 
| Public Shareholding (%) | 0 | 0 | 0 | 0 | 
| Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 
| Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 
| Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 
| Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 
| Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 
| Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 
| PBIDTM(%) | 28.82 | 20.7 | 46.26 | 17 | 
| PBDTM(%) | 23.12 | 16.3 | 40.23 | 13.05 | 
| PATM(%) | 15.43 | 15.24 | 23.85 | 6.98 | 
Senores Pharmaceuticals intends to fund the acquisition through proceeds from its IPO, which raised ₹5.82 billion in December.
Senores Pharmaceuticals shares closed 6% below their listing price, although they are still up 43% from the IPO price.








 IIFL Customer Care Number
 IIFL Customer Care Number 
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000  / 7039-050-000
 IIFL Capital Services Support WhatsApp Number
 IIFL Capital Services Support WhatsApp Number
+91 9892691696


IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.